MiR-221, acting as onco-miR or oncosuppressor-miR, plays an important role in tumor progression; however, the prognostic value of miR-221 in human carcinomas is controversial and inconclusive. The objective of our study was to conducted a systematic review and meta-analysis of miR-221 in various types of human cancers.
Methods
An online search of up-to-date electronic databases, including PubMed and Embase, was conducted to identify as many relevant papers as possible. 32 papers involving 3041 patients with different carcinomas were included in the analysis. Hazard ratios (HRs) of miR-221 were used to evaluate prognostic values.
Results
Thirty-two papers involving 15 cancers were included. MiR-221 was associated with a worse overall survival (OS) in patients, and a combined HR was 1.93 (95% CI of 1.43–2.60, 2080 patients, 22 studies, I-squared = 80.4%, P = 0.000); however, the combined HR for relapse-free survival (RFS) was 1.37 (95% CI of 0.75–2.48, 625 patients, 7 studies, I-squared = 78.8%, P = 0.000), and disease-free survival (DFS) was 1.24 (95% CI of 0.60–2.56, 539 patients, 5 studies, I-squared = 81.8%, P = 0.000).
Conclusion
MiR-221 was shown to be associated with a poor OS in human carcinomas, and thus may serve as a useful predictor of clinical outcomes.
Kangkang Liu and Lining Wang contributed to the work equally and should be regarded as co-first authors.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abkürzungen
ALL
Acute lymphoid leukemia
CI
Confidence interval
CMM
Cutaneous malignant melanoma
DFS
Disease-free survival
HR
Hazard ratio
OS
Overall survival
RFS
Relapse-free survival
Background
MicroRNAs (miRNAs), small noncoding single-stranded RNAs, play a pivotal role in diverse cellular processes through post-transcriptional regulation of gene expression [1]. MiRNAs are now known to play an essential role in malignancy, functioning as tumor suppressors and oncogenes [2]. The expression of miRNAs is abnormal in different carcinomas and miRNAs are involved in the development and progression of disease [3]. As favorable or unfavorable prognostic biomarkers, many miRNAs are associated with patients’ survival in different cancers [4‐6].
MiR-221, located on human chromosome X, is upregulated in many different cancers. As an onco or oncosuppressor-miR, miR-221 plays an important role in tumor progression [7]. High expression of miR-221 is associated with a worse survival in patients with different cancers, such as liver, laryngeal, and lung cancers [8‐10]. It has also been reported that miR-221 is a favorable factor in predicting the prognosis of ovarian and renal cancers [11, 12]. Because of the controversy involving the association between miR-221 and survival among patients with different carcinomas, we conducted a systematic review and meta-analysis of the prognostic value of miR-221 in human cancers.
Anzeige
Methods
Search strategy
The objective of our study was to summarize the prognostic value of miR-221 in human carcinomas. We conducted an online search of up-to-date electronic databases, including PubMed and Embase, to identify as many relevant papers as possible. The search was performed by professional literature librarian. The key words, “miR-221” and “cancer” were used. The details of the search strategy in two databases were shown (Additional file 6: Table S1). The reference lists of review papers were hand-searched for further relevant studies. The last search update was performed on July 20, 2019.
Risk of bias assessment
We systematically assessed the quality of all included studies according to the guidelines that we previously described [13]. The assessment details of the studies are as follows: 1) clear information about populations and nations of included participants; 2) clear information about the type of carcinomas involved; 3) clear information about study design (prospective or retrospective); 4) clear information about the arrays used to measure the expression of miR-221; 5) clear information about the type of outcome assessment; and 6) clear information about follow-up. Studies that met the above criteria were included.
The evaluation process was performed by two independent authors, all HRs were extracted directly from papers. The risk of bias was assessed by Cochrane B or Newcastle-Ottawa Scale (NOS).
Statistical analysis
All statistical analyses were conducted using Stata12.0. The HRs with corresponding 95% CIs were used to estimate the strength of the relationship between miR-221 and prognosis. The results were displayed by forest plots. The heterogeneity assumption of the pooled HR was verified by a χ2-based Cochran Q test and Higgins I2 statistic, with an I-squared> 50% and/or a P < 0.1 indicating heterogeneity. Considering the heterogeneity of different articles, a random effect was performed in this meta-analysis. Potential publication bias was determined by Begg’s test with a funnel plot.
Anzeige
Results
Characters of included studies
812 and 1192 papers were identified from the databases of Pubmed and Embase respectively. By browsing the titles and abstracts, the articles that were duplicates or not involved in the prognostic value of miR-221 in human cancers were excluded. Then, according to full-text assessment, 32 papers researching the prognostic value of miR-221 in human carcinomas with sufficient data were included in our study (Fig. 1). All included papers have relatively high-quality assessment of the risk of bias, which met the requirements for inclusion.
×
A total of 3041 patients with different cancers were involved, including ovarian cancer [11, 14], bladder cancer [15], osteosarcoma [16, 17], liver cancer [8, 18‐22], laryngeal cancer [9], thyroid cancer [23], lung cancer [10, 24], gastric-colon cancer [25‐28], renal cancer [12], breast cancer [29‐32], prostate cancer [33‐36], cutaneous malignant melanoma (CMM) [37], acute lymphoid leukemia (ALL) [38, 39], and NK/T-cell lymphoma [40]. 20 of them were conducted in Asia (18 in China and 2 in Korea), the remaining studies were conducted in other countries, including Greece, the USA, Egypt, Germany, Italy, and Brazil. The origins of miR-221 in most studies were derived from tumor tissues; 7 were from serum/plasma and 2 were from bone marrow. Quantitative real time PCR (qRT-PCR) was performed in most of the studies for quantification of miR-221; two studies used in-situ hybridization (ISH) to detect miR-221 expression. The details of these papers were summarized in Table 1.
Table 1
Characters of included 32 papers about the prognostic value of miR-221 in human carcinomas
Study
Nation
Patients
cancer
Survival
HR(95% CI)
P value
Origins
Measure
Cutoff
Analysis
Wu Q (2017)
China
74
Ovarian cancer
OS
0.395 (0.196–0.796)
0.009
Tumor
qRT-PCR
Median
Univariate
Tsikrika (2017)
Greece
159
Bladder cancer
DFS
PFS
0.712(0.380–1.335)
1.396(0.539–3.620)
0.290
0.492
Tumor
qRT-PCR
ROC
Univariate
Deng (2017)
China
125
Breast cancer
DFS
0.480 (0.263–0.879)
0.017
Tumor
qRT-PCR
Median
Multivariate
Nakka (2017)
USA
32
Osteosarcoma
OS
0.733(0.486–1.1055)
0.139
Tumor
qRT-PCR/ISH
Quartation
Multivariate
Xie D (2017)
China
70
Live cancer
OS
1.743 (1.004–3.772)
0.012
Tumor
qRT-PCR
Median
Multivariate
Hussein (2017)
Egypt
50
Laryngeal cancer
OS
6.5 (1.8–22.5)
0.003
Tumor
qRT-PCR
ROC
Univariate
Dai L (2017)
China
78
Thyroid cancer
RFS
1.41(1.14–1.95)
0.007
Tumor
qRT-PCR
Median
Multivariate
Chen F (2017)
China
135
HCC
DFS
OS
2.846 (1.564–5.181)
2.969 (1.629–5.408)
0.001
< 0.001
Tumor
qRT-PCR
Median
Multivariate
Zhang Y (2016)
China
104
Lung cancer
OS
1.873(1.267–2.768)
0.002
Tumor
qRT-PCR
Median
Multivariate
Yang Z (2015)
China
108
Osteosarcoma
OS
RFS
7.66(1.83–15.92)
6.82(1.33–13.69)
0.01
0.01
Serum
qRT-PCR
Median
Multivariate
Cai K (2015)
China
182
Colon cancer
OS
2.394 (1.210–4.910)
0.006
Tumor
qRT-PCR
Median
Multivariate
Tao K (2014)
China
90
Colon cancer
OS
2.043 (1.095–3.812)
0.025
Tumor
qRT-PCR
Median
Multivariate
Vergho (2014)
Germany
74
Renal cancer
CSS
0.47 (0.22–1.00)
0.0527
Tumor
qRT-PCR
ROC
Multivariate
Lv J (2014)
China
117
Lung cancer
OS
2.425 (1.314–4.475)
0.005
Tumor
qRT-PCR
Median
Multivariate
Li P (2014)
China
72
CMM
OS
DFS
3.189(1.782–6.777)
2.119(1.962–8.552)
0.007
0.01
Serum
qRT-PCR
Median
Multivariate
Gyongyosi B (2014)
Italy
20
HCC
OS
PFS
1.92(0.61–6.10)
1.32(0.47–3.66)
0.29
0.58
Tumor
qRT-PCR
Median
Univariate
Falkenberg (2013)
Germany
86
Breast cancer
MFS
2.57(1.1073–5.9647)
0.028
Tumor
qRT-PCR
ROC
Multivariate
Hong (2013)
China
96
Ovarian cancer
OS
2.243(1.1357–4.4300)
0.020
Serum
qRT-PCR
Mean
Multivariate
Gimenes (2013)
Brazil
48
ALL
OS
DFS
2.31(0.92–5.81)
1.54 (0.57–4.17)
0.074
0.391
Marrow
qRT-PCR
Median
Multivariate
Karakatsanis (2013)
Greece
60
HCC
OS
1.72 (1.32–2.50)
0.002
Tumor
qRT-PCR
Mean
Multivariate
Amankwah (2013)
USA
65
Prostate cancer
RFS
1.79 (0.67–4.76)
0.25
Tumor
qRT-PCR
Median
Multivariate
Liu K (2012)
China
92
Gastric cancer
OS
2.322 (1.1116–4.8505)
0.025
Tumor
qRT-PCR
Mean
Multivariate
Hanna (2012)
USA
377
Breast cancer
OS
0.70 (0.51–0.97)
0.0312
Tumor
ISH
Quartation
Multivariate
Kang (2012)
Korea
92
Prostate cancer
RFS
0.360 (0.171–1.896)
0.570
Tumor
qRT-PCR
Median
Univariate
Li J (2011)
China
46
HCC
OS
1.903(1.235–2.981)
0.018
Serum
qRT-PCR
Mean
Multivariate
Yoon (2011)
Korea
115
HCC
RFS
3.07 (1.56–6.07)
0.001
Tumor
qRT-PCR
Mean
Multivariate
Zhao R (2011)
China
93
Breast cancer
OS
6.871 (1.967–23.997)
0.003
plasma
qRT-PCR
Median
Multivariate
Schaefer (2010)
Germany
75
Prostate cancer
RFS
0.93 (0.3–2.89)
0.902
Tumor
qRT-PCR
Median
Univariate
Wang (2010)
China
32
ALL
OS
0.538(0.30–0.9648)
0.038
Marrow
qRT-PCR
Median
Multivariate
Spahn (2010)
Germany
92
Prostate cancer
RFS
0.525(0.29–0.95)
0.032
Tumor
qRT-PCR
ROC
Multivariate
Pu (2010)
China
103
Colon cancer
OS
3.478(1.038–11.654)
0.043
Plasma
qRT-PCR
Youden
Multivariate
Guo (2010)
China
79
Lymphoma
OS
5.714(1.782–18.18)
0.003
Plasma
qRT-PCR
Youden
Multivariate
Note: HCC Hepatocellular carcinoma; ALL Acute lymphoid leukemia; CMM Cutaneous malignant melanoma; ROC Receiver operating characteristic curve; Youden, Youden index; OS Overall survival; RFS Relapse-free survival; DFS Disease-free survival; PFS Progression-free survival; CSS Cancer-special survival; MFS Metastasis-free survival; qRT-PCR Quantitative Real Time PCR; ISH In-situ hybridization
Association of miR-221 with overall survival (OS)
A total of 22 articles researched the association between miR-221 and OS among different carcinomas. Generally, miR-221 was associated with a poor OS, with a pooled HR was 1.93 (95% CI of 1.43–2.60, 2080 patients, 22 studies, I-squared = 80.4%, P = 0.000) (Fig. 2). Due to the heterogeneity, subgroup analyses were performed. Most of the studies originated from China, thus we divided the patients into Asian (Chinese) and non-Asian groups. MiR-221 was significantly related to the OS of Chinese patients (HR = 2.14 (1.53–2.99), 1493 patients, 16 studies, I-squared = 74.2%, P = 0.000), but not non-Asian patients (HR = 1.44 (0.83–2.47), 587 patients, 6 studies, I-squared = 83.3%, P = 0.000) (Table 2 and Additional file 1: Figure S1). Then, we divided studies according to the number of included individuals. The combined HR was 2.28 (95% CI of 1.29–4.41, 1126 patients, 7 studies, I-squared = 85.9%, P = 0.000) in studies with more than 100 participants, and the HR was 1.80 (95% CI of 1.25–2.59, 954 patients, 15 studies, I-squared = 78.4%, P = 0.000) in studies with less than 100 patients (Table 2 and Additional file 2: Figure S2); however, heterogeneity still existed in these subgroups.
Table 2
Subgroup analysis of association between the expression of miR-221 and OS
Categories
Subgroups
No of studies
Pool HR
95% CI
Result
I2
P
All
OS
22
1.93
1.43–2.60
S
80.4%
0.000
Countries
Asian (Chinese)
16
2.14
1.53–2.99
S
74.2%
0.000
Non-Asian
6
1.44
0.83–2.47
NS
83.3%
0.000
Samples origins
Tumor tissues
13
1.61
1.13–2.29
S
81.4%
0.000
Serum/blood
7
3.25
2.15–4.92
S
42.2%
0.109
Marrow
2
1.07
0.26–4.43
NS
85.4%
0.009
Sample sizes
> 100
7
2.28
1.29–4.11
S
85.9%
0.000
≤100
15
1.80
1.25–2.59
S
78.4%
0.000
Cancer types
Colon cancer
4
2.33
1.60–3.38
S
0.0%
0.897
Liver cancer
5
1.91
1.53–2.38
S
0.0%
0.633
Lung cancer
2
2.02
1.45–2.81
S
0.0%
0.486
ALL
2
1.07
0.26–4.43
NS
85.4%
0.009
Breast cancer
2
2.02
0.22–18.81
NS
91.7%
0.001
Osteosarcoma
2
2.24
0.23–22.29
NS
93.7%
0.000
Ovarian cancer
2
0.94
0.17–5.17
NS
91.8%
0.000
Note: ALL Acute lymphoid leukemia; S Significant; NS Non-significant
×
We further analyzed the subgroups divided based on different cancers. The cancers investigated in more than one paper were included. The results showed that the HR was 2.33 (95% CI of 1.60–3.38, 467 patients, 4 studies, I-squared = 0.0%, P = 0.897) in colon cancer, 1.91 (95% CI of 1.53–2.38, 331patients, 5 studies, I-squared = 0.0%, P = 0.633) in liver cancer, and 2.02 (95% CI of 1.45–2.81, 221 patients, 2 studies, I-squared = 0.0%, P = 0.486) in lung cancer (Table 2 and Additional file 3: Fig. S3). However, the combined HR was 1.07 (95% CI of 0.26–4.43, 80 patients, 2 studies, I-squared = 85.4%, P = 0.009) in ALL, 2.02 (95% CI of 0.22–18.81, 470 patients, 2 studies, I-squared = 91.7%, P = 0.001) in breast cancer, 2.24(95% CI of 0.23–22.29, 140 patients, 2 studies, I-squared = 93.7%, P = 0.000) in osteosarcoma and 0.94 (95% CI of 0.17–5.17, 170 patients, 2 studies, I-squared = 91.8%, P = 0.000) in ovarian cancer (Table 2 and Additional file 4: Figure S4).
Interestingly, the origins of miR-221 in 7 of the papers were derived from serum or plasma. The combined HR was 3.25 (95% CI of 2.15–4.92, 597 patients, 7 studies, I-squared = 42.2%, P = 0.109), which suggested that the expression of miR-221 in serum/plasma was associated with a worse OS. The results differed from a previous study [41]. In addition, the combined HR of the studies from tumor tissues was 1.61 (95% CI of 1.13–2.29, 1403 patients, 13 studies, I-squared = 81.4%, P = 0.000), and the combined HR from marrow was 1.07 (95% CI of 0.26–4.43, 80 patients, 2 studies, I-squared = 85.4%, P = 0.009) (Table 2 and Additional file 5: Figure S5).
Association of miR-221 with relapse-free survival (RFS)/ disease-free survival (DFS)
Seven of papers reported an association between miR-221 and RFS. The combined HR was 1.37 (95% CI of 0.75–2.48, 625 patients, 7 studies, I-squared = 78.8%, P = 0.000) (Fig. 3a). Notably, 4 of them focused on prostate cancer. The combined HR was 0.74 (95% CI of 0.38–1.42, 324 patients, 4 studies, I-squared = 48.6%, P = 0.120), which demonstrated that miR-221 tended to be a favorable predictor of RFS in prostate cancer patients (Fig. 3b). Besides, 5 of studies focused on the DFS of patients, the combined HR was 1.24 (95% CI of 0.60–2.56, 539 patients, 5 studies, I-squared = 81.8%, P = 0.000) (Fig. 3c). Due to the limited number of papers mentioned about RFS/DFS of patients, we were not able to analyze the causes of heterogeneity.
×
Publication bias
Both Begg’s and Egger’s tests were performed to estimate the potential publication bias in our study. A P < 0.05 indicated the existence of publication bias. There was no apparent publication bias in papers with respect to RFS and DFS; however, we evaluated the potential publication bias with respect to OS (P = 0.015). The funnel plots of Begg’s test were shown in Fig. 4.
×
Discussion
MicroRNAs have been reported to be aberrantly expressed and play an important role in predicting the prognosis of human carcinomas [42]. It has been recommended to classify miRNAs into two categories (oncogenes and onco-suppressor miRNAs), which regulate tumor oncogenes or suppressor genes, respectively [43]. MiR-221, either as an oncogene or tumor suppressor gene, is involved in tumor progression in many different cancers. MiR-221 promotes the tumor progression of cancers, such as bladder, prostate, and breast cancers, by targeting downstream molecules, including PTEN, E-cadherin, and suppressors of cytokine signaling 1, 3 (SOCS1, 3) [44‐48]. In contrast, miR-221 inhibits tumor progression in diseases such as pancreatic and ovarian cancers, by targeting factors, such as SOCS3 and ADP-ribosylation factor-4 (ARF4) [11, 49]. Interestingly, the dual role of miR-221 has been found in some cancers, such as pancreatic cancer [49‐51]. It has been reported that some miRNAs (miR-21 and miR-155) are related to unfavorable clinical outcomes of pancreatic cancer [52]; however, there is still a lack of studies on the prognostic value of miR-221, which will be worth further exploration. Taken together, miR-221 has a dual role in tumor progression of different cancers. Future studies are necessary to elucidate the mechanisms underlying miR-221 in oncology.
Anzeige
The prognostic values of miR-221 have been investigated in different kinds of cancers; however, the roles of miR-221 in different studies have been controversial and inconclusive. A meta-analysis involving miR-221 in human cancers was conducted by Yang et al.in 2014 [53]. Subsequently, additional studies researching the prognostic value of miR-221 have been published in recent years and the results of those studies are inconsistent. Thus, an updated systematic review and meta-analysis was necessary to ascertain the prognostic value of miR-221.
Recently, Zhang et al. conducted a review and meta-analysis of the prognostic value of miR-221/miR-222 in human malignancy [54]; however, we noted that many relevant articles were omitted and some of the results should be re-summarized. Therefore, in the current study we systematically summarized the prognostic value of miR-221 according to the papers published in recent years. The results showed that miR-221 was associated with a worse OS of various of cancers. In agreement with our results, miR-222 (miR-221 highly homologous miRNA) was reported to be associated with poor survival [55]. Subgroup analysis showed that miR-221 was related to the OS of Chinese, but not non-Asians. Regarding different cancers, we found that miR-221 was significantly related to the OS of colon, liver, and lung cancers, but not associated with ALL, osteosarcoma, breast cancer, and ovarian cancer. With respect to the methods of miR-221 quantification, because there were limited articles using the ISH method, subgroup analysis using methods of miR-221 quantification did not produce meaningful results. In addition, the relationship between miR-221 and RFS/DFS of patients was indefinite, but high expression of miR-221 tended to be associated with a favorable RFS in prostate cancer patients. With the limited number of relevant papers, more studies are needed to confirm these conclusions.
Interestingly, Rong et al. reported that the association between the expression of miR-221 in serum/plasm and prognosis of patients was non-significant (HR = 0.94 (0.47–1.87), I-squared = 84.2%, P = 0.000) [41]; however, in our study, 7 papers focusing on miR-221 from serum/plasma were included. We found that miR-221 was related to a poor OS. The inconsistency of the two studies was possibly due to the different standards used in the articles, and more published studies were added in our study. The Guo et al. study was included in our study and Rong et al. study [40]. In the Guo’s study, the HR of multivariate analysis was calculated using high expression of miR-221 as a baseline. Therefore, the HRs directly obtained from this study should be transformed.
There were limitations in the current study that must be mentioned. First, the numbers of studies with some cancers were limited and it was difficult to conclude that a reliable association existed between miR-221 with those cancers. More studies researching miR-221 in different cancers will be necessary in the future. Second, although subgroup analysis was performed, the heterogeneity still existed in some groups. With the limited number of papers, we could not adequately explore the reasons for heterogeneity. Third, studies with negative results were generally less likely to be published. Therefore, we could not deny the potential existence of publication bias.
Anzeige
Conclusion
By summarizing the results of published papers about the prognostic value of miR-221 in human cancer, we found that high expression of miR-221 was associated with a worse OS; however, the association of miR-221 with RFS/DFS was not significant. Future studies with a larger number of cases are recommended to validate the role of miR-221 in human carcinomas.
Acknowledgements
The authors sincerely thank all medical staff who participates in this study.
Ethics approval and consent to participate
Not applicable.
Consent for publication
Not applicable.
Anzeige
Competing interests
The authors declare that they have no competing interests.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.
Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.
Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.
Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.
Update Onkologie
Bestellen Sie unseren Fach-Newsletterund bleiben Sie gut informiert.